WHO's 2026–2027 policy direction emphasizes strategic stockpiles of essential medical supplies, resilient emergency supply chains, research and development of medical countermeasures, therapeutics, and geographically diversified local and regional manufacturing.
Could validated, shelf-stable, donor-independent oxygen therapeutics eventually contribute to strategic medical preparedness?
BHOC has added a new External Policy Evidence analysis examining the contextual connection between blood-supply resilience, strategic reserves, distributed manufacturing and the emerging BHOC policy concept of Oxygen Security.
Read the full Evidence analysis → Strategic Stockpiles, Modular Manufacturing and Oxygen Security
This is contextual policy evidence. WHO has not evaluated or endorsed BHOC and has not designated BHOC as a medical countermeasure, strategic-stockpile product or pandemic-preparedness technology.